Home Allergy, IgE, and Mast Cell Markers Prostaglandin D2 Test: Mast Cell Activation, High Levels, and Meaning

Prostaglandin D2 Test: Mast Cell Activation, High Levels, and Meaning

By
Vita Library
-
1
Learn what a prostaglandin D2 urine metabolite test measures, how random and 24-hour collections differ, and what high, normal, or medication-affected results may mean.

A prostaglandin D2 test looks for evidence that the body is producing excess prostaglandin D2, a short-lived lipid mediator released in large amounts by activated mast cells. In clinical practice, laboratories usually do not rely on the unstable parent molecule. They measure a more durable urine metabolite, commonly 2,3-dinor-11β-prostaglandin F2α, in a random sample or a 24-hour collection. A high result can support mast-cell mediator release when it matches episodes such as flushing, hives, wheezing, abdominal symptoms, lightheadedness, or low blood pressure. It cannot diagnose mast cell activation syndrome or systemic mastocytosis by itself, and a normal value does not rule either condition out. The sample type, timing, creatinine correction, medication use, kidney function, and laboratory method all affect interpretation. Prostaglandin testing is most useful as one part of a planned evaluation that also considers acute and baseline tryptase, urinary N-methylhistamine, urinary leukotriene E4, the symptom pattern, and alternative explanations.

  • Most “prostaglandin D2” testing measures a stable urinary metabolite rather than PGD2 itself.
  • A high result supports increased prostaglandin production but is not specific for MCAS or mastocytosis.
  • Random urine is convenient; a complete 24-hour collection may better represent total daily excretion.
  • Results are often reported per gram of creatinine, so hydration and creatinine excretion affect the number.
  • Aspirin and other NSAIDs can lower prostaglandin metabolites; do not stop them unless the ordering clinician says it is safe.
  • Severe breathing problems, faintness, or rapidly progressing multisystem symptoms require emergency treatment, not confirmation by urine testing.

Table of Contents

PGD2 and the Metabolites Laboratories Measure

Prostaglandin D2, abbreviated PGD2, is made from arachidonic acid through the cyclooxygenase pathway. Unlike histamine and tryptase, which are stored in mast-cell granules, PGD2 is synthesized after the cell is activated. Mast cells are a major source, especially during allergic and systemic mediator reactions, although other cells and tissues can contribute smaller amounts.

PGD2 can cause or amplify several symptoms associated with mast-cell activation. It widens blood vessels, which may contribute to flushing, warmth, headache, and a drop in blood pressure. It can tighten airway smooth muscle, increase mucus, recruit eosinophils and type 2 immune cells, and influence sleep and pain pathways. These effects overlap with histamine and leukotrienes, so symptoms cannot identify the responsible mediator with certainty.

The parent molecule is unstable and is rapidly transformed. Direct plasma or urine PGD2 values therefore have a narrow collection window and substantial preanalytical limitations. Most current clinical laboratories instead measure a downstream metabolite that remains detectable in urine. Names on reports may include:

  • 2,3-dinor-11β-prostaglandin F2α;
  • 2,3-dinor-11 beta-prostaglandin F2 alpha;
  • 2,3 BPG;
  • 11β-PGF2α metabolite;
  • PGD2 metabolite, urine.

These labels can look interchangeable, but laboratories may target different molecules. Another research and specialty marker is tetranor-PGDM, a major urinary PGD2 metabolite. A result from one assay should not be compared directly with a cutoff from another.

Random urine reports commonly normalize the metabolite to urinary creatinine and use units such as picograms per milligram of creatinine. Creatinine correction helps account for how concentrated or dilute the urine is. A 24-hour test may also report a creatinine-normalized concentration or total excretion, depending on the laboratory.

One widely used laboratory method lists a random-urine reference value below 1,802 pg/mg creatinine. That number is method-specific, not a universal definition of mast-cell disease. Other laboratories may use another interval, age grouping, assay, or unit. Interpretation should use the exact test name and reference range printed on the report.

The test measures a biochemical trail, not the number of mast cells. A person can produce excess PGD2 because a normal number of mast cells activated strongly, because an increased mast-cell burden released more mediator, or because another inflammatory process contributed. Distinguishing those possibilities requires clinical context and other tests.

Why the Test Is Ordered

Clinicians order urinary PGD2 metabolite testing when symptoms suggest episodic or persistent mast-cell mediator release, particularly when serum tryptase is normal or was not collected during an event. It may be included with urinary N-methylhistamine and leukotriene E4 in a mast-cell mediator panel.

Symptoms that can prompt testing include recurrent combinations of:

  • flushing, itching, hives, or swelling;
  • nasal congestion, cough, wheeze, or chest tightness;
  • cramping, diarrhea, nausea, or vomiting;
  • headache, palpitations, lightheadedness, or fainting;
  • sudden low blood pressure or anaphylaxis.

A single symptom, especially one that is chronic and nonspecific, provides weak evidence. Mast cell activation syndrome generally involves recurrent systemic episodes affecting at least two organ systems, an objective mediator rise, and a meaningful response to treatment directed at mast-cell mediators or activation. The diagnosis also requires consideration of other diseases.

PGD2 metabolites may be useful in the initial assessment of systemic mastocytosis, a clonal disorder in which abnormal mast cells accumulate in tissue. Patients with systemic mastocytosis can have increased mediator production, but the urine test is a screening or supportive marker. Diagnosis depends on established criteria involving bone marrow or other tissue, mast-cell morphology, KIT variants, abnormal cell markers, baseline tryptase, and related findings.

The test is also used to compare a symptomatic period with a stable baseline. An event sample collected during or soon after characteristic symptoms may be more informative than a random sample obtained on a good day. Because the metabolite persists longer than parent PGD2, urine collection is easier than capturing a brief plasma peak.

Testing is less useful when ordered as broad screening for fatigue, brain fog, isolated gastrointestinal discomfort, or nonspecific chemical sensitivity without episodic mediator-type symptoms. Many common conditions can produce those complaints. An abnormal result in a low-probability setting is more likely to be incidental, method-related, or difficult to connect to the symptoms.

The result should answer a defined question. Examples include: Was a typical attack accompanied by increased PGD2 production? Is there repeated objective evidence of mast-cell mediator release? Does a patient with elevated baseline tryptase also have increased urinary mediators? Is treatment changing the biochemical pattern? Without a defined question, repeat testing can create numbers without a clear clinical action.

Random Versus 24-Hour Urine Collection

Both random and 24-hour urine testing are available. The better choice depends on symptom timing, practicality, and the performing laboratory’s instructions.

Random urine

A random, or spot, sample is easier to collect during a flare. It can be obtained at home or in a clinic and usually requires only a clean container and correct storage. The result is commonly divided by urine creatinine, producing a pg/mg creatinine value.

A spot sample works best when it is collected during a familiar episode or within several hours of it. Research summarized in recent reviews suggests that an acute-to-baseline increase in urinary PGD2 metabolite can support mast-cell activation. Exact ratio thresholds are still evolving and should not be applied across assays without specialist interpretation.

Very dilute urine can produce unstable calculations near the assay limits. Very concentrated urine, unusually low muscle mass, high muscle mass, pregnancy, kidney disease, and age can affect creatinine excretion. Creatinine correction reduces hydration effects but does not eliminate every source of variation.

Twenty-four-hour urine

A 24-hour collection captures excretion over an entire day and may smooth short fluctuations. Some laboratories prefer it for systemic mastocytosis screening. The tradeoff is collection burden and a greater chance of an incomplete sample.

A typical collection proceeds as follows:

  1. At the chosen start time, urinate and discard that first specimen.
  2. Record the start time.
  3. Collect every urine sample for the next 24 hours, including overnight urine.
  4. At the same time the next day, urinate once more and add that final specimen.
  5. Keep the container refrigerated or follow the laboratory’s specified storage instructions.
  6. Return the complete container with the total time and volume documented.

Missing even one void can lower total excretion and make the result unreliable. Collecting longer than 24 hours can raise it. The laboratory may use total creatinine to judge whether the collection appears complete, but this check is imperfect.

Some laboratories accept both methods but state that 24-hour urine is preferred. Others use a random sample specifically for event-versus-baseline comparison. Do not switch collection type between samples unless the clinician intends to do so, because a spot ratio and a total 24-hour result are not directly equivalent.

Preparation instructions vary. Some tests require no preservative and refrigeration; others allow certain preservatives. The container, storage temperature, and transport time matter. Obtain the kit and written instructions before the event when possible. A household container is not an acceptable substitute unless the laboratory explicitly approves it.

Interpreting a High Result

A high urinary PGD2 metabolite indicates that prostaglandin production exceeded the assay’s reference interval during the collection period. It becomes clinically persuasive when the elevation is reproducible, the sample coincides with characteristic symptoms, and other evidence points toward mast-cell activation.

The following pattern provides stronger support than an isolated abnormality:

  • recurrent sudden episodes involving two or more organ systems;
  • a clearly elevated event sample compared with a properly collected baseline;
  • a simultaneous rise in another mediator, such as tryptase, N-methylhistamine, or leukotriene E4;
  • improvement with appropriately selected anti-mediator treatment;
  • no better explanation after targeted evaluation.

A high value does not identify the trigger. IgE-mediated allergy, a medication reaction, insect venom exposure, temperature change, exercise, alcohol, infection, or a clonal mast-cell disorder can all lead to mediator release. The clinician must reconstruct the exposure timeline separately.

The result also does not predict how severe the next episode will be. PGD2 contributes to flushing, airway symptoms, and vascular effects, but clinical severity depends on the total mediator mix, target-organ sensitivity, asthma, cardiovascular disease, dose and route of exposure, treatment delay, and other factors. A modest urine elevation does not guarantee mild disease, and a large elevation does not mean that every future episode will cause anaphylaxis.

Several non-mastocytosis conditions can elevate the marker. Laboratory guidance notes that diffuse urticaria, angioedema, and some myeloproliferative diseases may produce high values without diffuse mast-cell proliferation. PGD2 metabolites have also been studied in asthma, aspirin-exacerbated respiratory disease, inflammatory arthritis, and other disorders. That broader biology is why the marker is supportive rather than diagnostic.

Persistent elevation between attacks may reflect ongoing mediator production, repeated unrecognized triggers, an increased mast-cell burden, another inflammatory source, medication effects, or biological variation. It should prompt a structured review rather than an automatic label. Baseline serum tryptase, blood counts, kidney function, symptom records, and specialist assessment help define the next step.

When a result is only slightly above the cutoff, analytical variation matters. A number of 1,850 pg/mg against a cutoff of 1,802 pg/mg is not equivalent to a many-fold increase. Borderline results deserve confirmation under a clear protocol, especially if the collection occurred without symptoms or medication preparation differed.

Normal and Inconclusive Results

A normal result means the tested urine did not contain an elevated amount of the measured metabolite relative to the laboratory range. It does not rule out mast-cell activation, MCAS, anaphylaxis, or systemic mastocytosis.

Reasons for a normal test despite genuine mediator episodes include:

  • collection occurred outside the symptomatic window;
  • the episode released more histamine or leukotrienes than PGD2;
  • aspirin or an NSAID suppressed cyclooxygenase-dependent production;
  • a 24-hour collection was incomplete;
  • urine was stored incorrectly;
  • kidney or creatinine factors altered the reported ratio;
  • the disorder is intermittent and the baseline happened to be quiet.

Mast cells do not release every mediator in a fixed proportion. One patient may show a clear tryptase rise, another may have elevated leukotriene E4, and another may have a PGD2 metabolite increase. Even within the same person, the pattern can differ by trigger and episode.

A low value has no established deficiency meaning. There is no recognized target for “optimal PGD2” in healthy people. The pathway serves normal immune and physiological functions. Treatment decisions should address symptoms and disease, not attempt to raise a low urine metabolite.

An inconclusive result includes a borderline elevation, a sample collected without a timestamp, a test performed while medication preparation was uncertain, or a creatinine value suggesting an extremely dilute specimen. The best response is often to improve the next collection rather than interpret the number more aggressively.

Comparing event and baseline specimens can add context. Use the same laboratory, assay, sample type, and storage process when possible. Record symptom severity, timing, medications, menstrual or illness context, and collection start and end. A diary turns two isolated numbers into a clinically interpretable pair.

A normal urine marker should never be used to dismiss a clear episode of anaphylaxis. Anaphylaxis is diagnosed from symptoms and timing. Epinephrine treatment is based on the clinical event, not on whether a later urine test crosses a reference limit.

Medications and Other Influences

Aspirin and nonsteroidal anti-inflammatory drugs, or NSAIDs, inhibit cyclooxygenase enzymes and can lower prostaglandin production. One major laboratory recommends, when medically feasible, avoiding aspirin for two weeks and other NSAIDs for 72 hours before collection. Those instructions are test-specific and are not safe for everyone.

Do not stop prescribed aspirin used after a heart attack, stroke, stent, or other cardiovascular condition without the prescribing clinician’s approval. Stopping can create a serious clotting risk. NSAIDs may also be important for pain or inflammatory disease. If a medication cannot be held, document the drug, dose, and last use so the result can be interpreted with that limitation.

Aspirin deserves extra caution in mast-cell disorders. It can reduce PGD2-driven flushing in selected patients, but it can also provoke severe reactions, particularly in people with aspirin-exacerbated respiratory disease or prior NSAID reactions. Aspirin treatment or challenge should not be started from a urine result without specialist supervision.

Other influences include:

  • Kidney function: Urinary excretion and creatinine normalization may change with renal impairment.
  • Hydration: Creatinine correction helps, but extremely dilute samples can still be problematic.
  • Age and muscle mass: Both affect creatinine excretion and may shift a ratio.
  • Collection completeness: Missed urine lowers a 24-hour total.
  • Storage: Warm or prolonged storage can degrade analytes or allow contamination.
  • Acute inflammation: Asthma, urticaria, infection, or another inflammatory state may increase prostaglandin pathways.
  • Timing: A sample from a symptom-free day may not represent a short flare.

Diet is a major concern for some urinary histamine measurements, but it is not generally the principal preparation issue for this PGD2 metabolite assay. Follow the laboratory’s own written restrictions rather than borrowing a diet list from another mast-cell test.

Menstrual-cycle effects, exercise, smoking, and circadian variation have been discussed for eicosanoid pathways, but clinical cutoffs are not routinely adjusted for all of them. Consistency between paired collections is more useful than trying to eliminate every normal biological influence.

Building a Complete Mast-Cell Evaluation

The urine result should lead to a proportionate next step. The appropriate pathway differs for a person with one allergic reaction, someone with repeated unexplained episodes, and someone with persistently elevated baseline tryptase.

For a suspected acute allergic reaction, document the suspected exposure, dose, symptom onset, organ systems involved, and treatment response. Targeted allergy testing may include skin-prick testing, specific IgE, component testing, or a supervised challenge. A PGD2 metabolite cannot determine whether a food, drug, venom, or environmental allergen caused the event.

For recurrent systemic episodes, clinicians often combine:

  • acute and baseline serum tryptase;
  • event and baseline urinary PGD2 metabolite;
  • urinary N-methylhistamine;
  • urinary leukotriene E4;
  • complete blood count and metabolic testing;
  • evaluation for allergy, medication reactions, and common mimics.

Tryptase remains the most accepted event marker when a meaningful acute rise over the person’s baseline is documented. Urinary mediators can add sensitivity and are easier to collect after leaving a clinic. A panel can be useful, but more tests also create more chances for a borderline abnormality. Results should be judged as a pattern, not counted as votes.

If systemic mastocytosis is a concern, baseline tryptase, skin findings, unexplained anaphylaxis, osteoporosis, blood-count abnormalities, enlarged organs, and KIT testing may influence referral. Bone marrow biopsy is reserved for situations where the overall probability and established criteria justify it. A high PGD2 metabolite alone is not enough.

Conditions that can mimic mediator episodes include chronic urticaria, uncontrolled asthma, panic attacks, vasovagal syncope, heart rhythm problems, menopause, thyroid disease, medication side effects, carcinoid syndrome, pheochromocytoma, hereditary angioedema, and gastrointestinal disorders. The symptom pattern should guide which alternatives are tested.

A useful appointment summary includes:

  • the exact test name and units;
  • the laboratory reference interval;
  • random or 24-hour collection type;
  • collection time relative to symptoms;
  • urine creatinine and total volume when reported;
  • aspirin and NSAID use;
  • concurrent mediator results;
  • a brief event diary.

Ask the clinician whether the value is clearly abnormal or borderline, whether it should be repeated during a defined flare, and what finding would change treatment. Also ask whether the medication preparation was safe and adequate. Repeated testing has value only when the result will answer a question or monitor a planned intervention.

Treatment is directed at the diagnosed condition and dominant symptoms. It may include trigger avoidance, H1 or H2 antihistamines, leukotriene modifiers, mast-cell stabilizing approaches, asthma therapy, or specialist-directed treatment for a clonal disorder. Drugs that alter prostaglandin production require particular caution. A laboratory elevation is not, by itself, a reason to start aspirin.

During a rapidly progressing reaction with breathing difficulty, throat or tongue swelling, collapse, or multisystem symptoms, follow the emergency plan and use epinephrine when indicated. Urine can be collected later if safe. Preserving a sample is never more important than preserving airway, breathing, and circulation.

References

Disclaimer

This article provides general information and cannot diagnose mast cell activation syndrome, systemic mastocytosis, anaphylaxis, or another disorder. Medication changes, especially stopping cardiovascular aspirin or starting aspirin for flushing, require clinician supervision. Seek emergency care for severe or rapidly progressing allergic symptoms; laboratory testing must not delay epinephrine when it is indicated.

RELATED ARTICLESMORE FROM AUTHOR